Ether lipid biosynthetic pathway

The ether lipid biosynthetic pathway is a complex multi-step metabolic sequence essential for the production of ether-linked glycerophospholipids, including plasmalogens, which are critical for membrane integrity, vesicular fusion, and antioxidant defense (PubMed: 28935473). The pathway is initiated within the peroxisome by the enzymes glyceronephosphate O-acyltransferase (GNPAT) and alkylglycerone phosphate synthase (AGPS), with subsequent steps occurring in the endoplasmic reticulum (UniProt: P09110, P50443). Dysregulation of this pathway leads to severe genetic disorders such as Rhizomelic Chondrodysplasia Punctata (RCDP) and Zellweger syndrome, which are characterized by profound ether lipid deficiencies and systemic developmental defects (NORD, PubMed: 31215033). Additionally, altered ether lipid levels are associated with neurodegenerative diseases like Alzheimer’s, and high AGPS activity is frequently observed in aggressive cancers, facilitating tumor cell survival and migration (PubMed: 21252243, 25215243). Therapeutic interventions focus on restoring deficient lipid levels through precursor replacement therapy, such as PPI-1011, or by inhibiting overactive enzymes in oncogenic contexts (PubMed: 26084050). Because this is a metabolic pathway rather than a single molecular target, it involves a variety of proteins across different cellular compartments, requiring highly specific therapeutic approaches to avoid broad lipid imbalances (PubMed: 30121303).

Other names

Plasmalogen biosynthetic pathwayEther phospholipid synthesis pathwayAlkylglycerolipid metabolismPeroxisomal ether lipid pathway

Therapeutic strategies involve the use of synthetic plasmalogen precursors to bypass deficient peroxisomal enzymatic steps or the inhibition of specific pathway enzymes like AGPS to disrupt oncogenic lipid signaling in cancer cells (PubMed: 26084050, 21252243).